Lilly Reports One-Year Results for Taltz and Zepbound
Indianapolis, Indiana, United States, November 11, 2026 Eli Lilly and Company has announced detailed 52-week Phase 3b clinical results...
psoriatic arthritis
Advertisement
UCB Reports Sustained BIMZELX Responses in Psoriatic Arthritis
Atlanta, Georgia, United States, November 9, 2026 UCB, a global biopharmaceutical company, has announced additional Week 24 findings from...
Sun Pharma Wins FDA Approval for ILUMYA in Psoriatic Arthritis
MUMBAI, India and PRINCETON, New Jersey, U.S., October 30, 2026 Sun Pharmaceutical Industries Limited (Sun Pharma) has announced that...
Monte Rosa Therapeutics Earns $37.5M Milestone as Novartis Starts Second Phase 2 Trial of MRT-6160
BOSTON, Massachusetts, United States — October 28, 2026 Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company developing molecular glue...
Johnson & Johnson Reports TREMFYA Axial PsA Study Data
Spring House, Pennsylvania, September 25, 2026 Johnson & Johnson announced topline results from the Phase 4 STAR study evaluating...
Advertisements
Bristol Myers Squibb Reports Durable Sotyktu Results in PsA
PRINCETON, N.J. — September 17, 2026 Bristol Myers Squibb announced positive two-year results from the Phase 3 POETYK PsA-2...
Greywolf Therapeutics Advances GRWD0715 Into axSpA Trial
LONDON — September 8, 2026 Greywolf Therapeutics announced that it has dosed the first participants with axial spondyloarthritis (axSpA)...
Spyre Reports SPY072 Rheumatoid Arthritis Phase 2 Results
WALTHAM, Mass. — August 25, 2026 Spyre Therapeutics, Inc. announced topline results from the rheumatoid arthritis (RA) sub-study of...
MoonLake Reports Positive Phase 3 PsA Results for Sonelokimab
ZUG, Switzerland, August 10, 2026 MoonLake Immunotherapeutics announced positive topline results from its Phase 3 IZAR-1 trial evaluating investigational...
MoonLake Reports Strong Phase 3 Sonelokimab HS Results
ZUG, Switzerland, June 21, 2026 MoonLake Immunotherapeutics has announced compelling Week 52 results from its Phase 3 VELA clinical...
Advertisement
